Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Leukemia 10Burkitt Lymphoma 9Recurrence 8Lymphoproliferative Disorders 6Lymphoma, Non-Hodgkin 5Lymphatic Diseases 5Immunoproliferative Disorders 4Neoplasms 3Neoplasm, Residual 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Lymphoid 2Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Large Granular Lymphocytic 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Hematologic Neoplasms 1Bites and Stings 1

Interventions

Rituximab 40Cyclophosphamide 29Etoposide 15Doxorubicin 14Vincristine 13Prednisone 13ibrutinib 10fludarabine 10fludarabine phosphate 8Cytarabine 8Mycophenolic Acid 7Bortezomib 7Lenalidomide 6Carmustine 6pembrolizumab 5Peripheral Blood Stem Cell Transplantation 5Melphalan 5Inotuzumab Ozogamicin 5Whole-Body Irradiation 4Tacrolimus 4Carboplatin 4CT-P10 4Brentuximab Vedotin 4Antilymphocyte Serum 4tositumomab I-131 3tocilizumab 3tazemetostat 3obinutuzumab 3idelalisib 3etoposide phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, B-Cell × blinatumomab × Clear all
NCT02910063 2021-01-13

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

Amgen

Phase 2/3 Completed
41 enrolled 18 charts
LymphoidOther hematologic neoplasm

Leukemia, Neoplasms, Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡